ZENTIVA KS

Their core work

Zentiva KS is the Czech subsidiary of Zentiva Group, one of Europe's leading generic pharmaceutical companies, specializing in the development, manufacture, and commercialization of generic medicines. In EU research projects, Zentiva contributes as an industrial partner — hosting researchers, providing access to real-world pharmaceutical manufacturing environments, and applying academic insights to practical drug formulation challenges. Their project involvement spans the full pharmaceutical development pipeline: from early preformulation and dosage form design through biopharmaceutical characterization and bioavailability modeling. They bridge the gap between academic drug research and industrial-scale pharmaceutical production, making them a high-value industry anchor in academic-led consortia.

What they specialise in

How they've shifted over time

In the 2018–2021 period, Zentiva's EU project involvement centered on classical pharmaceutical sciences: preformulation, pharmaceutical technology, dosage form development, and biorelevant dissolution — the experimental wet-lab foundations of generic drug development. By the 2021–2024 period, the focus shifted decisively toward computational and predictive methods: PBPK modelling, in vitro-to-in vivo correlation, machine learning, and explicitly animal-free approaches (3Rs). This is a meaningful transition — from characterizing physical drug behavior in the lab to predicting it in silico, reflecting broader industry pressure to reduce animal testing and accelerate development timelines through digital tools.

Zentiva is moving toward computational pharmaceutics and in silico prediction tools, suggesting future collaboration value for partners working on digital bioequivalence, PBPK platforms, or regulatory acceptance of animal-free testing strategies.

How they like to work

Zentiva participates exclusively as a consortium partner — never as project coordinator — which is typical for large pharmaceutical companies in MSCA projects, where they primarily serve as industrial hosts and applied research environments rather than research drivers. Their two projects involved broad consortia, giving them exposure to 23 partners across 13 countries, suggesting they are comfortable operating in large, internationally distributed networks. Working with Zentiva likely means access to an industrial pharmaceutical site, manufacturing expertise, and the credibility of a regulated commercial environment, rather than research leadership.

Zentiva has collaborated with 23 unique partners across 13 countries through just two projects, indicating high network density relative to participation volume. Their European footprint spans a wide geographic range, consistent with MSCA training networks that deliberately include diverse academic and industry nodes.

What sets them apart

Zentiva KS is one of very few large-scale generic pharmaceutical manufacturers with active H2020 project participation, giving them a rare combination of industrial production reality and academic research connectivity. For consortium builders, they offer what most university partners cannot: a regulated manufacturing environment where formulation hypotheses can be tested against commercial constraints. Their shift toward computational and animal-free development also positions them as an early-mover industrial adopter of next-generation regulatory science tools.

Highlights from their portfolio

• ORBIS
  The larger of the two projects (EUR 332,100) and the entry point for Zentiva into EU research collaboration, covering the broadest range of pharmaceutical development competencies from medicinal chemistry through technology transfer.
• InPharma
  Represents a strategic pivot — an animal-free, fully computational approach to oral drug product development, combining PBPK modelling and machine learning, signaling Zentiva's alignment with the EU's 3Rs regulatory direction.